IPIC Message Board - Msg: 2112888

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC

IPIC 0.0001000

0.0%

Dec 18 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: P.Prazeres who wrote (620)	9/4/1997 10:00:00 AM
From: Graham Marshman	of 1359

Good news and bad news: More Redux news on 52% sales reduction in WSJ. ...and the good news "Interneuron Pharmaceuticals 07/22/97, DONALDSON, LUFKIN & JENRETTE SECURITIES Investext Abstracts via Dow Jones COMPANY REPORT - number 1937815 By To, A., et al Estimated Investext information units for report: 33.2 Words: 4730 Interneuron Pharmaceuticals reported that the results from two phase 3 trials were done on citicholine. There are a few blemishes in the data, which is not surprising considering the complex nature of stroke patients' overall health status. The group of patients who had suffered moderate to severe stroke showed definitive improvement at 500 milligram dose. They received a score of 95 or greater on the 100-point Barthel Index, compared to placebo-treated patients. In the second study, 41% of citicholine-treated patients with an NIH stroke score of eight or greater (moderate to severe stroke) achieved a Barthel Index greater than or equal to 95, compared to 25% of placebo-controlled patients. Citicholine is very safe and is already on the market in more than 20 countries." Graham

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next